Redx Pharma
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
FDA approves Jazz Pharmaceuticals’ Modeyso as first drug for ultra-rare brain cancer
H3 K27M-mutant diffuse midline glioma affects an estimated 2,000 people in the US every year
EC approves Jazz Pharmaceuticals’ Ziihera for advanced biliary tract cancer
Approximately 26% of biliary tract cancer patients globally have HER2-positive disease
Roche/Jazz share positive phase 3 results for lung cancer combination therapy
Approximately 30,000 new cases of small cell lung cancer are reported in the US every year
Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn
The companies will aim to discover new antibody-based therapeutics for cancer
Jazz shares positive results for Zepzelca combination in phase 3 lung cancer study
Approximately 30,000 new cases of small cell lung cancer are reported in the US every year
Innovative Trials Announces New Charity Partnerships
Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year
Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership
The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...
Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate
STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio
New technique enables study of immune response to cancer using archived tissue samples
FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples
Gilead and Merus announce oncology partnership worth over $1.5bn
The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies